XWELL, Inc. Files 8-K, Details Corporate History

TL;DR

XWELL, Inc. (formerly XpresSpa Group) filed an 8-K, mostly historical corporate name changes.

AI Summary

XWELL, Inc. filed an 8-K on March 12, 2024, to report other events and financial statements. The filing indicates a name change from XpresSpa Group, Inc. to XWELL, Inc. on January 5, 2018, and previously from Form Holdings, Inc. on January 2, 2018. The company is incorporated in Delaware and its principal executive offices are located in New York, NY.

Why It Matters

This filing provides a historical record of XWELL, Inc.'s corporate identity changes, which can be important for understanding its evolution and potential past liabilities or affiliations.

Risk Assessment

Risk Level: low — The filing primarily concerns historical corporate name changes and does not appear to disclose new material financial or operational information.

Key Players & Entities

• XWELL, Inc. (company) — Registrant
• XpresSpa Group, Inc. (company) — Former Company Name
• Form Holdings, Inc. (company) — Former Company Name
• March 12, 2024 (date) — Report Date
• January 5, 2018 (date) — Date of Name Change
• January 2, 2018 (date) — Date of Name Change

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share XWEL The Nasdaq Stock Mar
• $15.9 million — ne-year extension totaled approximately $15.9 million. Under the March 2024 extension, the pr
• $36.7 million — and scope were expanded to an estimated $36.7 million or more for the extension with new coll

Filing Documents

• tm248531d1_8k.htm (8-K) — 25KB
• tm248531d1_ex99-1.htm (EX-99.1) — 16KB
• 0001104659-24-033244.txt ( ) — 216KB
• xwel-20240312.xsd (EX-101.SCH) — 3KB
• xwel-20240312_lab.xml (EX-101.LAB) — 33KB
• xwel-20240312_pre.xml (EX-101.PRE) — 22KB
• tm248531d1_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. On March 12, 2024, XWELL, Inc. (the "Company") issued a press release announcing that the Company, together with Ginkgo Bioworks and the Centers for Disease Control and Prevention (the "CDC"), are expanding the CDC's Traveler-based Genomic Surveillance program to new collection locations at US international airports in Miami (MIA) and Chicago (ORD). XpresTest began conducting the bio-surveillance monitoring program with the CDC in collaboration with Concentric by Ginkgo in 2021. As previously disclosed, the program was renewed in August 2023 through a new one-year contract. At that time, we estimated that revenue from such one-year extension totaled approximately $15.9 million. Under the March 2024 extension, the program funding and scope were expanded to an estimated $36.7 million or more for the extension with new collection locations at U.S. international airports in Miami (MIA) and Chicago (ORD) and the roll out of multi-pathogen testing across the program.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K (the "Form 8-K") and the press release attached hereto include "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Forward-looking statements relating to expectations about future results or events, including the Company's current expectations relating to the bio-surveillance monitoring program, are based upon information available to XWELL as of today's date and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XWELL, or other matters and attributable to XWELL or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XWELL does not undertake any obligation to publicly update any of these

forward-looking statements to reflect events or circumstances that may arise after the date hereof

forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated March 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XWELL, Inc. Date: March 12, 2024 By: /s/ Cara Soffer Name: Cara Soffer Title: General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR